Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
Alyaa ElhazmiVincent PellegrinoAwad Al-OmariHani N MuftiHend SallamMohammed S AlshahraniAhmed MadyAdnan AlghamdiAli AltalaqMohamed H AzzamAnees SindiAyman KharabaZohair A Al-AseriGhaleb A AlmekhlafiWail TashkandiSaud A AlajmiFahad FaqihiAbdulrahman AlharthyJaffar A Al-TawfiqRami Ghazi MelibariYaseen M ArabiPublished in: Journal of clinical medicine (2023)
The tocilizumab treatment in critically ill COVID-19 patients admitted to the ICU improved the overall 28 day hospital survival, which might not be influenced by the concurrent use of other COVID-19 medical therapeutics, although further research is needed to confirm this.